论文部分内容阅读
抑制骨髓移植时移植物抗宿主反应是临床研究的主要课题。迄今虽试用了抗T细胞单克隆抗体等各种方法,而治疗仍然是选用免疫抑制剂。由于类固醇制剂、咪唑硫嘌呤、球磷酰胺等都有强的副作用,因之渴望开发新的免疫抑制剂。近年有CyclosporinA和Mizoribine(MZR)二种免疫抑制剂问世。 MZR是从子囊菌的培养液中提取的,具有咪唑核的嘌呤代谢抑制剂。它对免疫的影响有:抑制小白鼠抗体产生,抑制NK活性,抑制淋巴细胞混合培养反应以及抑制各种致有丝分裂原所引起的淋巴细胞转化反应
Graft-versus-host response to bone marrow transplantation is a major issue in clinical research. Although so far tried a variety of methods such as anti-T cell monoclonal antibody, and treatment is still the use of immunosuppressive agents. Because of steroid formulations, azathioprine, phosphatidylethanolamine and so have strong side effects, and therefore eager to develop new immunosuppressive agents. In recent years, Cyclosporin A and Mizoribine (MZR) two kinds of immunosuppressive agents come out. MZR is a purine metabolic inhibitor with imidazole nucleus extracted from the broth of ascovells. Its impact on immunity are: inhibition of mouse antibody production, inhibition of NK activity, inhibition of lymphocyte mixed culture reaction and inhibition of a variety of mitogen-induced lymphocyte transformation reaction